Atypical antipsychotic drugs (APDs) increase dopamine (DA) release in prefrontal cortex (PFC), an effect probably mediated by the direct or indirect activation of the 5-HT 1A receptor (5-HT 1A R). Given the very low in-vitro affinity of most APDs for 5-HT 1A Rs and the large co-expression of 5-HT 1A Rs and 5-HT 2A receptors (5-HT 2A Rs) in the PFC, this effect might result from the imbalance of 5-HT 1A R and 5-HT 2A R activation after blockade of these receptors by APDs, for which they show high affinity. Here we tested this hypothesis by examining the dependence of the APD-induced DA release in medial PFC (mPFC) on each receptor by using in-vivo microdialysis in wild-type (WT) and 5-HT 1A R and 5-HT 2A R knockout (KO) mice. Local APDs (clozapine, olanzapine, risperidone) administered by reverse dialysis induced a dosedependent increase in mPFC DA output equally in WT and 5-HT 2A R KO mice whereas the DA increase was absent in 5-HT 1A R KO mice. To examine the relative contribution of both receptors to the clozapineinduced DA release in rat mPFC, we silenced G-protein-coupled receptors (GPCRs) in vivo with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) while 5-HT 1A Rs or 5-HT 2A/2C Rs in the mPFC were selectively protected with the respective antagonists WAY-100635 or ritanserin. The inactivation of GPCRs while preserving y70 % of 5-HT 2A/2C Rs prevented the clozapine-induced DA rise in mPFC. In contrast, clozapine increased DA in mPFC of EEDQ-treated rats whose 5-HT 1A Rs were protected (y50 % of control rats). These results indicate that (1) 5-HT 1A Rs are necessary for the APDs-induced elevation in cortical DA transmission, and (2) this effect does not require 5-HT 2A R blockade by APDs.
Introduction
Cognitive impairment, including attention disorders, deficits in working memory and executive functions, is a central feature of schizophrenia lacking adequate treatment (Braff, 1993 ; Elvevag & Goldberg, 2000 ; Green et al. 2000) . Negative symptoms are also poorly treated with current medications (Weickert et al. 2000) , which, by themselves, induce this type of symptomatology (Artaloytia et al. 2006) . In particular, atypical antipsychotic drugs (APDs) improve negative symptoms and quality of life more than classical antipsychotics (Sumiyoshi et al. 2006 ; Woodward et al. 2005) . Moreover, some APDs (amisulpride, clozapine, olanzapine, risperidone) proved superior to firstgeneration drugs when considering their overall efficacy (Leucht et al. 2009 ).
The ability of some APDs to improve negative/ cognitive symptoms (Bubenikova-Valesova et al. 2008 ; Grayson et al. 2007 ; Harvey et al. 2008 ) has been attributed to their capacity to increase dopamine (DA)-mediated transmission in the medial prefrontal cortex (mPFC) and hippocampus of experimental animals (Assié et al. 2005 ; Bortolozzi et al. 2007b ; Chung et al. 2004 ; Díaz-Mataix et al. 2005 ; Elsworth et al. 2008 ; Ichikawa et al. 2001 ; Kuroki et al. 1999 ; Li et al. 2009 ; Millan, 2000 ; Rollema et al. 1997 Rollema et al. , 2000 Youngren et al. 1999) . Indeed, an optimal DA transmission is fundamental for the execution of PFC-dependent cognitive tasks (Vijayraghavan et al. 2007 ; Williams & Goldman-Rakic, 1995) and, among other anatomical and neurochemical abnormalities in PFC, schizophrenia patients show a reduced dopaminergic innervation (Akil et al. 1999 ; Lewis & Lieberman, 2000) .
APDs share a higher in-vitro affinity and in-vivo occupancy of 5-HT 2A receptors (5-HT 2A Rs) vs. DA D 2 receptors (Meltzer et al. 1989 ; Nyberg et al. 1998 ; Stockmeier et al. 1993) . 5-HT 2A Rs are densely expressed in PFC, mainly in projection pyramidal neurons (Amargó s- Bosch et al. 2004 ; Ló pez-Giménez et al. 1997 ; Pazos et al. 1985 ; Santana et al. 2004) , including those projecting to the ventral tegmental area (VTA) (Vázquez-Borsetti et al. 2009 ). 5-HT 2A R stimulation in PFC enhances the activity of pyramidal neurons projecting to the VTA (Puig et al. 2003 (Puig et al. , 2005 and of VTA dopaminergic neurons , leading to an increased mesocortical DA release Gobert & Millan, 1999) . Further, the 5-HT 2A R antagonist M100907 reduced the firing of DA neurons and DA release in mPFC Minabe et al. 2001 ; Pehek et al. 2001) . Overall, these observations are consistent with the above anatomical finding showing the existence of (a) closed mPFC-VTA loops (Carr & Sesack, 2000) and (b) the expression of 5-HT 2A Rs in mPFC pyramidal neurons projecting to the VTA (Vázquez-Borsetti et al. 2009 ). However, 5-HT 2A R blockade has been suggested to be necessary for APDs to enhance DA release in the mPFC (Bonaccorso et al. 2002 ; Ichikawa et al. 2001 ; Liégeois et al. 2002) .
In addition to 5-HT 2A R blockade, APDs display variable, but often high affinity for other monoamine receptors (see http://kidb.case.edu/pdsp.php ; Roth et al. 2003) . Agonist activity at 5-HT 1A receptors (5-HT 1A Rs) by APDs appears to contribute to their superior efficacy in treating non-psychotic symptoms (Bantick et al. 2001 ; Meltzer & Sumiyoshi, 2008 ; Millan, 2000 ; Sumiyoshi et al. 2001a, b ; but see Rënyi et al. 2001 ; Yasuno et al. 2003) . Hence, although APDs show little or no in-vitro affinity for 5-HT 1A Rs (K i = 770 nM for clozapine, >1000 nM for olanzapine and 490 nM for risperidone ; Arnt & Skarsfeldt, 1998 ; Bymaster et al. 1996) , these agents increase cortical DA release through 5-HT 1A R activation Rollema et al. 1997) .
Given the large co-expression of 5-HT 1A and 5-HT 2A receptors in PFC (Amargó s- Bosch et al. 2004) and their opposite role in modulating pyramidal neuron activity (Aghajanian & Marek, 1997 ; Amargó s-Bosch et al. 2004 ; Araneda & Andrade, 1991 ; Ashby et al. 1994 ; Puig et al. 2005) , the apparent in-vivo action of APDs at 5-HT 1A Rs might be due to blockade of 5-HT 2A Rs in cells co-expressing both receptors, thus enhancing 5-HT 1A R-mediated neurotransmission. Here we examined this possibility using control mice and mice lacking 5-HT 1A or 5-HT 2A receptors. We also used an in-vivo rat model consisting in the inactivation of Gprotein-coupled receptors (GPCRs) with the alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), while selectively protecting 5-HT 1A or 5-HT 2A/2C receptors in the mPFC (Amargó s-Bosch et al.
2004).

Materials and methods
Animals
Male albino Wistar rats (250-320 g) were from Iffa Credo (France). Male homozygous 5-HT 1A R knockout (KO) mice were generated at Princeton University) (Parks et al. 1998 ) and 5-HT 2A R KO mice were generated at Columbia University) (Fiorica-Howells et al. 2002) . Both genotypes were gradually backcrossed to the C57BL/6 background. From these initial sources, some 5-HT 1A R KO and 5-HT 2A R KO mice were transferred to develop a stable colony in our animal facilities. Wild-type (WT) mice of the same genetic background (C57BL/6) were also used. Mice were aged 10-15 wk at the time of experiments. Animals were maintained in a temperature-controlled room with a 12-h light/dark cycle (lights on 08:00 hours). Food and water were available ad libitum. Animal care followed the European Union regulations (O.J. of E.C. L358/1 18/12/1986) and was approved by the Institutional Animal Care and Use Committee of the School of Medicine, University of Barcelona.
Drugs and reagents
All reagents used were of analytical grade and were obtained from Merck (Germany). 5-HT oxalate, clozapine, 1-[2,5-dimethoxy-4-iodophenyl-2-aminopropane] (DOI), dopamine hydrochloride, EEDQ, risperidone, ritanserin, pyridin-3-yl carbamoyl] indoline (SB-242084), spiperone and N-[2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl]-N-(2-pyridyl) cyclohexane carboxamide 3 HCl (WAY-100635) were from Sigma/RBI (Spain). BAY x 3792, citalopram HBr and olanzapine were from Bayer, Lundbeck A/S (Denmark) and Eli Lilly (USA), respectively. To assess local effects in microdialysis experiments, drugs were dissolved in perfusion fluid [aCSF (artificial cerebrospinal fluid, mM) : NaCl, 125 ; KCl, 2.5 ; CaCl 2 , 1.26 and MgCl 2 , 1.18] and administered by reverse dialysis at the stated concentrations (uncorrected for membrane recovery). Clozapine, olanzapine and risperidone were initially dissolved in a drop of acetic acid and diluted to appropriate concentrations in aCSF. All other drugs were dissolved in distilled water, saline or aCSF, as required. Concentrated solutions (1 mM ; pH adjusted to 6.5-7 with NaHCO 3 when necessary) were stored at x80 xC and working solutions were prepared daily by dilution in aCSF. Control mice and rats were perfused with aCSF. Bars in the figures show the period of drug administration, corrected for the void volume of the system.
Microdialysis procedures
Microdialysis experiments in rats and mice were conducted as described previously (Amargó s- Bosch et al. 2004 ; Bortolozzi et al. 2003) . Rats were anaesthetized with sodium pentobarbital (60 mg/kg i.p.) and implanted with 4-mm concentric dialysis probes (Cuprophan) in the mPFC [coordinates in mm : AP +3.2, L x0.8, DV x6.0 (Paxinos & Watson, 2005) ].
Experiments were performed in awake animals y20 h after surgery. Probes were perfused with aCSF at 1.5 ml/min. After an initial 100 min stabilization period, four baseline samples were collected (20 min each) before local drug administration, and successive dialysate samples were collected. For mice, the surgical and microdialysis procedures were identical to those described for rats, except for the dose of anaesthesia (40 mg/kg i.p.), length of dialysis membrane (2 mm), and the brain coordinates (in mm) of the mPFC : AP +2.2, L x0.2, DV x3.4 (Franklin & Paxinos, 1997) .
Monoamine concentration in dialysate samples was determined by HPLC with electrochemical detection (Hewlett Packard 1049 ; +0.75 for DA, +0.6 V for 5-HT) as described previously Díaz-Mataix et al. 2005) . Detection limits were 2-3 fmol for DA and 5-HT.
At the end of the experiments, animals were killed by an overdose of anaesthetic. Brains were quickly removed and frozen in dry ice before being sectioned (40 mm) with a cryostat (HM500-Om Microm, Germany) in coronal planes. Brain sections were stained with Neutral Red to verify the correct placement of probes. (Gozlan et al. 1994) , except those whose binding pockets are occupied. Thus, the perfusion of WAY-100635 or ritanserin in mPFC confers a selective protection of 5-HT 1A Rs or 5-HT 2A/2C Rs in mPFC, respectively, during EEDQ treatment. These two experimental groups are designated as GPCRsilenced+5-HT 1A R-protected and GPCR-silenced+ 5-HT 2A/2C R-protected, respectively.
Three to four hours after implantation, microdialysis probes were perfused with WAY-100635 (300 mM) for 3 h at 1.5 ml/min (5-HT 1A R protection). One hour after starting the perfusion, EEDQ (dissolved in ethanol/water 1 : 1) was administered at 6 mg/kg i.p. The same procedure was applied to protect 5-HT 2A/2C Rs using the 5-HT 2A/2C R antagonist ritanserin (300 mM). Control rats received vehicle intraperitoneally and aCSF through the dialysis probes. On the following day, histological or microdialysis experiments were performed. For autoradiographic studies, 14-mm-thick coronal sections were cut, thawmounted onto 3-aminopropyltriethoxysilane (APTS ; Sigma/RBI, Spain) coated slides, and kept at x20 xC until required. All experiments with control and EEDQ-treated rats were run in parallel.
Receptor autoradiography
To determine the extent of regional 5-HT 1A R or 5-HT 2A/2C R protection in EEDQ-treated rats we performed receptor autoradiography for 5-HT 1A and 5-HT 2A/2C receptors using the ligands [
3 H]8-OH-DPAT (227.0 Ci/mmol) and [
3 H]mesulergine (83.0 Ci/ mmol), respectively, from Amersham (GE Healthcare, Spain). Fresh frozen coronal sections of PFC from control and EEDQ-treated rats were used. Incubation conditions for [
3 H]8-OH-DPAT were as previously described (Mengod et al. 1996) . Non-specific binding was defined as that remaining in presence of 10 x5 M
5-HT. Incubation conditions for [
3 H]mesulergine were as previously described (Ló pez-Giménez et al. 2002 ; Pazos et al. 1985) . Non-specific binding was defined as that remaining in the presence of 10 x5 M mianserin. After incubation and washing, tissue sections were dipped in distilled, ice-cold water and dried rapidly under a cold air stream. Tissues were exposed to tritium-sensitive film (Kodak Biomax MR ; Kodak, USA) together with plastic 3 H standards for 60 d at 4 xC. All tissue sections used for quantification of receptor sites were processed simultaneously under the same conditions. 5-HT 1A , 5-HT 2A and 5-HT 2C receptors were examined in mice brain by receptor autoradiography as previously described (Ló pez-Giménez et al. 2002 ; Mengod et al. 1996 ; Pazos et al. 1985) using ( 
Data and statistical analysis
Microdialysis results are expressed as fmol/30-ml fraction for DA and 5-HT and shown in the Figures as percentages of baseline (individual means of four predrug fractions). Area under the curve (AUC) of selected time periods (fractions 6-16) was also calculated. Statistical analysis was performed using one-or twoway ANOVAs for repeated measures or AUC of DA or 5-HT values followed by Newman-Keuls post-hoc test.
Quantitative autoradiographic measurements obtained from the different radioligands were analysed using one-way ANOVA followed by Newman-Keuls post-hoc test or Student's t test, as appropriate. Data are expressed as means¡S.E.M. Statistical significance has been set at the 95 % confidence level (two tailed).
Results
Basal values of DA and 5-HT in mPFC dialysates
Basal extracellular levels of DA and 5-HT in dialysates from mPFC of mice and rats are shown in Table 1 . Non-significant differences were found between mice genotype or between control and EEDQ-pretreated rats. Table 2 . No genotype differences between the densities of 5-HT 2C Rs and 5-HT 1A Rs were found in receptor-rich areas such as the choroid plexus and PFC, respectively (Fig. 2b, c) .
5-HT
Perfusion of aCSF did not significantly alter DA and 5-HT output in the mPFC of WT and 5-HT 2A R KO mice (DA, n=6 and 5, respectively ; 5-HT, n=5 for each genotype) (Fig. 3 a, b ). Local administration of DOI (100 mM for 5-HT and 300 mM for DA ; see Bortolozzi et al. 2003 Bortolozzi et al. , 2005 ) enhanced 5-HT and DA output in the mPFC of WT mice ( Fig. 3 c, d ). DOI induced a maximal elevation of the 5-HT output to 205¡19 % of baseline (n=10) [F(15, 135) =7.71, p<0.001]. Similarly, DOI elevated DA output to 192¡23 % of baseline (n=10) [F(15, 135)=6.46, p<0.001] . Neither of these effects was observed when DOI was perfused in the mPFC of 5-HT 2A R KO mice ( Fig. 3 c, d ).
Effect of atypical antipsychotics on mPFC DA output in 5-HT 1A R and 5-HT 2A R KO mice These experiments were conducted to examine whether the increase in DA output induced by APDs in mPFC is primarily associated with activation of 5-HT 1A Rs or with blockade of 5-HT 2A Rs. Local administration of clozapine (300 mM), olanzapine (100 mM) and risperidone (100 mM) by reverse dialysis increased the DA concentration similarly in the mPFC of WT and 5-HT 2A R KO mice. Two-way ANOVAs revealed a significant effect of time and non-significant effects of genotype and timergenotype interaction (Fig. 4 a-c) . However, clozapine (300 mM), olanzapine (100 mM) and risperidone (100 mM) were unable to increase DA output in the mPFC of 5-HT 1A R KO mice (n=4-6) (Fig. 4 a-c In addition, the local perfusion of clozapine and olanzapine at increasing concentrations (30-100-300 mM) significantly raised DA concentration in mPFC of both WT and 5-HT 2A R KO, but not in 5-HT 1A R KO mice in a concentration-dependent manner (Fig. 5 a, b) . Unlike DA, the concentration of 5-HT in mPFC dialysates was similarly affected by clozapine (300 mM) and olanzapine (100 mM) in the three genotypes. A marginal reduction was noted in WT and 5-HT 2A R KO, but not in 5-HT 1A R KO mice (p=0.09 for clozapine ; p=0.17 for olanzapine ; one-way ANOVA of AUCs) (Fig. 5 c) .
Effect of clozapine on mPFC DA output after GPCR silencing with selective protection of 5-HT 1A or 5-HT 2A/2C receptors in rats
To assess the involvement of 5-HT 1A and 5-HT 2A receptors in the clozapine-induced increase of DA output in rat PFC, we examined its effect in control Clozapine perfusion (300 mM) increased the DA output in control rats (n=10) to 170¡14 % of baseline but to a much lower extent (a transient increase to 121¡ 24 % of baseline) in rats with preserved 5-HT 2A/2C Rs (n=5) (Fig. 6 a) We also tested the role of mPFC 5-HT 1A Rs in the clozapine-induced DA release in rats using the EEDQ model. 5-HT 1A Rs were unilaterally protected in rat mPFC by local administration of WAY-100635 (300 mM) during EEDQ treatment (see Methods section). In this group of rats, clozapine (300 mM) elicited a significant DA elevation (299¡57 % of baseline, n= 6) which was greater than in control rats (170¡ 14 % of baseline, n=10 ; see above) (Fig. 6 b) Previous studies have shown that clozapine reversed the increase of cortical 5-HT release induced by DOI . Since DOI also elevates DA release in mPFC by a 5-HT 2A R-dependent mechanism , we examined whether clozapine was able to counteract the increase in DA output induced by DOI, despite its ability to increase DA output by itself. DOI (300 mM) was locally administered in the mPFC of control rats and of EEDQ-treated rats with protected 5-HT 2A/2C Rs (n=6 and 8, respectively). DOI increased DA output in control rats and in those treated with EEDQ (with protected 5-HT 2A/2C Rs). Two-way ANOVAs revealed a significant effect of time [time effect : F(9, 108)=18.88, p<0.0001 ; nonsignificant effects of the group or timergroup interactions ; fractions 1-10) (Fig. 7 a) . The co-perfusion of clozapine (300 mM) reversed the effect of DOI on DA output in the mPFC of control rats but not of those treated with EEDQ with protected 5-HT 2A/2C Rs [group effect : F(1, 12)=11.58, p<0.005 ; time effect : F(15, 180)=8.87, p<0.0001 ; timergroup interaction : F(15, 180)=3.69, p<0.0001 ; fractions 1-16] suggesting that this effect does not involve blockade of 5-HT 2A Rs.
To examine the involvement of 5-HT 1A Rs in the clozapine-mediated reversal of DOI action on PFC DA output, we conducted additional experiments in which we evaluated the ability of the 5-HT 1A agonist BAY x 3702 to antagonize the DOI-mediated DA increase. The local perfusion of 30 mM BAY x 3702 reversed the DA elevation in PFC induced by local DOI administration [group effect : F(1, 7)=31.60, p<0.0008 ; time effect : F(15, 105)=7.26, p<0.0001 ; timergroup interactions : F(15, 105)=3.04, p<0.0001] (Fig. 7 b) . EEDQ-treated rats. EEDQ evoked a massive reduction of 5-HT 1A R and 5-HT 2A/2C R density (Figs. 8 and 9 ). Local, unilateral ritanserin perfusion by reverse dialysis in the mPFC partially avoided 5-HT 2A/2C R inactivation by EEDQ. Densities of 5-HT 2A/2C Rbinding sites in the ipsilateral (protected) mPFC at AP coordinates (in mm) 3.20-3.70 ranged from 61 % to 83 % (mean 71¡4 %, n=4 rats) relative to mPFC of control rats in the same hemisphere (n=2). In the contralateral (unprotected) side, 5-HT 2A/2C R-binding sites were 31¡2 % (n=4 rats) relative to the mPFC in the same hemisphere of control rats (n=2). One-way ANOVA indicated that [
3 H]mesulergine binding in ipsilateral mPFC of the GPCR-silenced+5-HT 2A/2C Rprotected group was significantly different from contralateral mPFC (p<0.001) (Fig. 8a, b) . Coronal sections from an AP coordinate distant from local ritanserin administration (e.g. 4.20 mm), revealed a marginally significant difference between ipsilateral and contralateral sides (68¡3 vs. 43¡3 % relative to PFC in the same hemispheres of control rats, respectively, p=0.058). Figure 9 a shows autoradiograms of 5-HT 1A Rs in PFC at AP 3.20-3.70 mm from different groups of rats : control (n=2), GPCR-silenced (n=2), GPCRsilenced+5-HT 2A/2C R-protected (n=4) and GPCRsilenced+5-HT 1A R-protected (n=4). WAY-100635 perfusion partially protected 5-HT 1A Rs from inactivation by EEDQ. One-way ANOVA indicated that [
3 H]8-OH-DPAT binding in ipsilateral PFC of the GPCR-silenced+5-HT 1A R-protected group was significantly different from contralateral PFC (51¡7 vs. 17¡4 % relative to ipsilateral and contralateral cortices of control rats, respectively, p<0.001) (Fig. 9 b) . In this case, 5-HT 1A R density was also significantly different between both ipsilateral and contralateral mPFC at AP y4.20 mm of GPCR-silenced+5-HT 1A R-protected rats (data not shown).
Discussion
The main finding of the present study is that APDs such as clozapine, olanzapine and risperidone do not require interaction with 5-HT 2A Rs to elevate DA release in rodent mPFC. This observation is relevant to understanding the neurobiological basis of the superior therapeutic action of these APDs in schizophrenia (Leucht et al. 2009 ) and may help to develop new drugs overcoming the limitations of existing treatments.
Methodological considerations
Two experimental models have been used in the present study : (a) mice lacking 5-HT 1A or 5-HT 2A receptors, and (b) rats, whose GPCRs were inactivated by EEDQ using selective protection of 5-HT 1A or 5-HT 2A/2C receptors. The lack of 5-HT 1A Rs in KO mice (Parks et al. 1998 ) was assessed by receptor autoradiography, electrophysiology and microdialysis (Amargó s-Bosch et al. 2004 ; present study). Here we extend these observations to 5-HT 2A R KO mice (Fiorica-Howells et al. 2002) . A preliminary account of these data has been presented previously (Bortolozzi et al. 2007a) . We show the absence of compensatory changes of 5-HT 1A R and 5-HT 2C R proteins in mice lacking 5-HT 2A Rs, similarly to Popa et al. (2005) who reported an unaltered 5-HT 2C R mRNA expression in 5-HT 2A R KO mice. Consistent with the autoradiographic data, the preferential To examine the role of 5-HT 1A and 5-HT 2A/2C receptors in rat PFC, we used a previously described model (Amargó s- Bosch et al. 2004) , consisting in the selective protection of one or other receptor from the inactivating action of EEDQ (Battaglia et al. 1987 ; Gozlan et al. 1994 ; Keck & Lakoski, 2000) through the local administration of antagonists (WAY-100635 or ritanserin, respectively) to occupy 5-HT 1A or 5-HT 2A/2C receptors in mPFC during EEDQ treatment. This model is far from the specificity of KO mice yet it allows for a preliminary examination of the involvement of 5-HT 1A and 5-HT 2A receptors on the effects of APDs in the rat brain.
The present autoradiographic data indicate that (1) EEDQ produces a massive loss of 5-HT 1A and 5-HT 2A/2C receptors in vivo, and (2) the local protection of 5-HT 1A or 5-HT 2A/2C receptors by the respective antagonists was relatively successful, as shown by differences in receptor density between (a) ipsilateral (protected) and contralateral (unprotected) mPFCs, (A1) controls (rats received the EEDQ vehicle i.p. and aCSF through the dialysis probe), (A2) GPCR-silenced rats (injected with 6 mg/kg i.p EEDQ and perfused with aCSF through the dialysis probe), (A3) GPCR-silenced+5-HT 1A R-protected rats (treated with 6 mg/kg i.p. EEDQ while 300 mM WAY-100635 was perfused through the dialysis probe), and (A4) GPCR-silenced+5-HT 2A/2C R-protected rats (treated with 6 mg/kg i.p. EEDQ while 300 mM ritanserin was perfused through the dialysis probe). A5 shows non-specific binding. Panels A1a-A4a are photomicrographs showing enlargements of the marked area in panels A1-A4. Note the higher 5-HT 2A/2C R binding in ipsilateral (protected) mPFC with respect to the contralateral (unprotected) side of panel A4 and the very low occupancy for 5-HT 2A/2C Rs in both hemispheres of panels A2 and A3. Scale bars, 2 mm (A1-A4) and 500 mm (A1a-A4a). (b) Densitometric quantification of 5-HT 2A/2C R binding in mPFC including cingulate, prelimbic and infralimbic cortices of the different group of rats (B1-B4). Bars represent mean 5-HT 2A/2C R fmol/mg tissue ¡S.E.M. of 4-8 observations (two or four observations at left and right hemispheres of two consecutive sections per animal and two to four animals per group). ** p<0.001 significantly different from corresponding contralateral (C) and ipsilateral (I) mPFC of control rats, ++ p<0.001 significantly different from contralateral mPFC of GPCR-silenced+5-HT 2A/2C R-protected rats, using one-way ANOVA followed by Newman-Keuls post-hoc test.
and (b) the ipsilateral side in EEDQ-treated and control rats. The fact that receptor densities in protected sides were lower than in control rats may be partly due to the damage caused by the dialysis probe, which forced us to use coronal sections relatively distant from the administration site, and thus, with lower antagonist occupancy than sites close to the microdialysis probes receiving a higher antagonist concentration. 5-HT 1A Rs have a great sensitivity to EEDQ in vitro (Gozlan et al. 1994 ). The present in-vivo data are consistent with this view, since EEDQ reduced 5-HT 1A and 5-HT 2A/2C receptor densities to 15 % and 30 % of controls, respectively. Similar differences have been noted for DA D 1 and D 2 receptors (see Cox & Waszczak, 1993 ; Hemsley & Crocker, 2001 and references therein). Interestingly, despite measured receptor densities in protected sides being lower than 100 % of controls, DOI increased DA release to the same extent in the mPFC of control rats and of those receiving Despite the diverse pharmacological profiles of APDs (Arnt & Skarsfeldt, 1998) , they share the ability (A1) controls (rats received the EEDQ vehicle i.p. and aCSF through the dialysis probe), (A2) GPCR-silenced rats (injected with 6 mg/kg i.p. EEDQ and perfused with aCSF through the dialysis probe), (A3) GPCR-silenced+5-HT 2A/2C R-protected rats (injected with 6 mg/kg i.p. EEDQ while 300 mM ritanserin was perfused through the dialysis probe), and (A4) GPCR-silenced+5-HT 1A R-protected rats (injected with 6 mg/kg i.p. EEDQ while 300 mM WAY-100635 was perfused through the dialysis probe). A5 shows non-specific binding. Panels A1a-A4a are photomicrographs showing enlargements of the marked area in panels A1-A4. Note the higher 5-HT 1A R binding in ipsilateral (protected) mPFC with respect to the contralateral (unprotected) side of A4 and the very low occupancy for 5-HT 1A Rs in both hemispheres of panels A2 and A3. Scale bars, 2 mm (A1-A4) and 500 mm (A1a-A4a). (b) Densitometric quantification of 5-HT 1A R binding in mPFC including cingulate, prelimbic and infralimbic cortices of the different group of rats (B1-B4). Bars represent mean 5-HT 1A R fmol/mg tissue ¡S.E.M. of 4-8 observations (two or four observations at left and right hemispheres of two consecutive sections per animal and two to four animals per group). ** p<0.001 significantly different from corresponding contralateral (C) and ipsilateral (I) mPFC of control rats, ++ p<0.001 significantly different from contralateral mPFC of GPCR-silenced+5-HT 1A R-protected rats, using one-way ANOVA followed by Newman-Keuls post-hoc test.
to increase DA release in rodent mPFC through 5-HT 1A R activation (Bortolozzi et al. 2007b ; Díaz-Mataix et al. 2005 ; Ichikawa et al. 2001 ; Li et al. 2009 ; Rollema et al. 1997 Rollema et al. , 2000 . This effect was attributed to simultaneous blockade of 5-HT 2A and D 2 receptors (Ichikawa et al. 2001) yet it seems to depend exclusively on the activation of 5-HT 1A Rs in mPFC (Bortolozzi et al. 2007b ; Díaz-Mataix et al. 2005) . In the present study, we further confirm these previous observations in 5 The apparent bell-shaped dose-effect relationship of olanzapine on DA release (Fig. 5 b) suggests the involvement of other prefrontal monoaminergic receptors (e.g. a 1 -adrenoceptors ; Amargó s-Bosch et al.
2003) for which olanzapine shows nM affinity (Arnt & Skarsfeldt, 1998) .
The similar in-vivo DA increases in PFC produced by several APDs Ichikawa et al. 2001) , does not bear a relationship with their invitro affinities for 5-HT 1A Rs, e.g. high for ziprasidone, low for clozapine and risperidone (yet clozapine occupies 5-HT 1A Rs in vivo ; Chou et al. 2003) or negligible for olanzapine (Arnt & Skarsfeldt, 1998 ; Bymaster et al. 1996 ; Newman-Tancredi et al. 1998 ). The exact way by which APDs lacking in-vitro affinity interact in vivo with 5-HT 1A R-mediated neurotransmission is unclear. The DA output induced by APDs and 5-HT 1A agonists was cancelled by co-perfusion with the GABA A antagonist bicuculline, suggesting the involvement of 5-HT 1A Rs in GABA interneurons . Given the inhibitory nature of 5-HT 1A Rs, a preferential action of APDs on 5-HT 1A Rs located on GABA interneurons would eventually result in an increased excitatory cortical output to the VTA to enhance DA neuron activity (Gessa et al. 2000) , an effect qualitatively similar to that of selective 5-HT 1A agonists .
The increase in mPFC DA release produced by APDs might theoretically result from an interaction between 5-HT 1A and 5-HT 2A receptors in neurons coexpressing these receptors (Amargó s- Bosch et al. 2004 ). Thus, 5-HT 2A R blockade by APDs might alter the physiological balance between 5-HT 1A and 5-HT 2A receptors, resulting in an increase of 5-HT 1A R-mediated neurotransmission. However, the present data do not support this possibility, since the APDs clozapine, olanzapine and risperidone increased a similar DA release in the mPFC of mice lacking 5-HT 2A Rs (with no alteration of 5-HT 1A R density) and in WT controls. These results in mice were confirmed by rat data showing that clozapine was ineffective in enhancing DA output in the mPFC of rats whose 5-HT 1A Rs were inactivated (y15 % of controls), yet whose 5-HT 2A/2C Rs were protected (y70 % of controls).
Interestingly, and despite its ability to stimulate DA release when given alone, clozapine counteracted the increase in PFC DA output induced by DOI, suggesting a different effect in PFC in basal or stimulated conditions. This pattern is similar to that observed in some electrophysiological studies, where clozapine displays a state-dependent action, reducing neuronal hyperactivity (e.g. Homayoun & Moghaddam, 2007 ; Kargieman et al. 2007 ; Schwieler & Erhardt, 2003) . Thus, clozapine would activate the mesocortical DA system from basal conditions but would dampen cortical hyperactivity.
Clozapine could not reverse the effect of DOI in GPCR-silenced+5-HT 2A/2C R-protected rats. In this group, 5-HT 2A Rs were entirely functional, as indicated by the local effect of DOI on DA output, comparable to that in controls. The inability of clozapine to counteract DOI's effect in these rats suggests the involvement of other receptors, different from 5-HT 2A Rs, to reverse the action of DOI in control rats. Although we could not perform a systematic study, the comparable effect of clozapine and the selective 5-HT 1A R agonist BAY x 3702 suggests the involvement of 5-HT 1A Rs.
Overall, these findings indicate that the stimulation of mesocortical DA release by APDs does not require the presence of 5-HT 2A Rs and suggest that these drugs activate 5-HT 1A Rs to enhance cortical DA neurotransmission. Alternatively, it is conceivable that other receptor-receptor interactions might explain this marked discrepancy between in-vitro and in-vivo actions of APDs at 5-HT 1A Rs.
Functional consequences
The present data, obtained in mice and rats using two different experimental models (permanent 5-HT receptor KO mice and GPCR inactivation with selective protection of 5-HT receptors) indicate that blockade of 5-HT 2A Rs by APDs is not a necessary step to elevate DA release and that this effect is mediated by indirect activation of 5-HT 1A Rs in PFC. The molecular/cellular basis of the present in-vivo results is not known.
These observations do not preclude at all that 5-HT 2A R blockade by APDs participates in their therapeutic action. Our conclusions are restricted to the role of 5-HT receptors required to enhance mesocortical DA, an effect potentially important for the actions of APDs on negative symptoms and cognitive deficits of schizophrenia patients. Given the lack of adequate treatment of these problems, further detailed studies are required to examine the ability of APDs -and in particular, of clozapine -to stimulate cortical 5-HT 1A R-mediated neurotransmission despite their low or negligible in-vitro affinity.
